Promising SINEs for Embargoing Nuclear–Cytoplasmic Export as an Anticancer Strategy 527

Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies 538

Précis: Intermittent combined use of the RAF inhibitor vemurafenib and the MEK inhibitor cobimetinib in a patient with BRAF-mutant melanoma and NRAS-mutant leukemia controlled both diseases. See commentary, p. 510

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib 546

Précis: The identification of two activating MTOR mutations in a patient who experienced a complete response to everolimus and pazopanib suggests an underlying mechanism of mTOR inhibitor sensitivity. See commentary, p. 513

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity 554

Précis: Activating MTOR mutations are widespread in human cancers and correlate with hypersensitivity to mTOR pathway inhibition. See commentary, p. 513
Vemurafenib treatment was previously shown to uncover an NRAS-mutant chronic myelomonocytic leukemia (CMML) in a patient with BRAF-mutant metastatic melanoma. Abdel-Wahab and colleagues report that the combination of vemurafenib and the MEK inhibitor cobimetinib blocked vemurafenib-induced CMML proliferation and restored normal white blood cell counts in this patient. Intermittent administration of vemurafenib and cobimetinib has durably maintained a near-complete melanoma response and has prevented CMML progression in association with decreased levels of CMML-derived circulating tumor DNA and reduced ERK activation in monocytes. Intermittent combination RAF and MEK inhibitor therapy may thus be useful for treatment of RAS-driven malignancies arising due to paradoxical activation of wild-type RAF by RAF inhibitors in RAS-mutant cells. For details, please see the article by Abdel-Wahab and colleagues on page 538.
### Updated version
Access the most recent version of this article at:
http://cancerdiscovery.aacrjournals.org/content/4/5

### E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

### Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

### Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.